Sanofi is continuing to splash the cash for autoimmune and immunology assets this spring by penning a new deal with ...

The startup, affiliated with China-based antibody designer Helixon Therapeutics, is developing bispecific drugs aimed at ...

Sanofi (SNY) stock slips as the company's asthma therapy amlitelimab fails in a Phase 2 trial, despite its plans to evaluate ...

Earendil Labs, an expert in AI-driven research and development of next-generation biologics therapeutics, and Sanofi have ...

Sanofi reports amlitelimab improved lung function in asthma, with new phase 3 trials planned across its respiratory pipeline.

Sanofi has said “deal” to Chrissy Teigen. The model, cookbook author and “Deal or No Deal” banker has signed on as a ...

Earendil Labs will collaborate with Sanofi SA in a $1.8 billion license deal. Earendil, which specializes in artificial intelligence-based R&D for biologics, is getting $125 million up front and $50 ...

Here is the complete list of companies whose shares will trade ex-date on April 17, 2025, along with their key corporate ...

Sanofi India is divesting its insulin brand, Lantus, with Glenmark, Dr. Reddy's, and Emcure Pharma considering acquisition, though a licensing agreement remains a possibility. The asking price has ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Novo Nordisk (NVO – Research Report) and ...

Drilling down into subgroups of patients, Sanofi also claimed that amlitelimab demonstrated “compelling efficacy” in patients with heterogeneous inflammatory asthma. This would “potentially represent ...

When we think about the protection that can be provided by a comprehensive immunization plan, we think in terms of lifetimes. It’s vital that we also remember the important moments that make up each ...